|By Business Wire||
|June 2, 2014 11:44 AM EDT||
Pharmaceutical Product Development, LLC (PPD) today announced it has been selected as one of the most innovative organizations using information technology to create business value by CIO magazine’s 27th annual CIO 100 Awards.
PPD earned recognition for PreclarusTM, its comprehensive technology solution that delivers real-time data and dynamic analytics to enable effective decision-making in clinical research. Preclarus consolidates large amounts of clinical trial data and allows clients to explore data more quickly and generate deeper insights to guide the research process.
“The increasing intelligence made possible with real-time data and robust analytics is evolving and enhancing the conduct of clinical trials,” said Mike Wilkinson, executive vice president and chief information officer of PPD. “Preclarus supports cutting-edge research, such as adaptive trial designs and PPD’s adaptive and intelligent approach to risk-based monitoring, which is changing the way clinical teams perform their jobs, while maintaining high quality and close oversight of clinical trial sites.”
Combining the use of analytical data reports with efficient processes for turning those reports into actionable findings, Preclarus provides early recognition of trends, early identification of risks, and more immediate, effective decisions and actions to improve study quality and efficiency. Preclarus dashboards offer real-time, interactive visualizations and analytics that allow users to drill down into data for detailed information.
“The advantage of Preclarus is that it’s not simply industry-leading technology, but rather a robust combination of our process, people and organization behind the data,” said Paul Colvin, PPD’s executive vice president, global clinical development. “Preclarus is a powerful tool providing data integration, predictive analytics, transparency and an unprecedented reporting scope, giving PPD clients actionable data at their fingertips to inform critical decision-making for successful clinical trials.”
PPD will accept the award during the CIO 100 Symposium & Awards Ceremony, Aug. 17-19, in Rancho Palos Verdes, California, and will be featured in the Aug. 1 issue of CIO magazine.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Preclarus and its potential value, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: rapid technological advances that make our services or capabilities less competitive; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; risks associated with acquisitions and investments; PPD’s ability to win new business; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.
May. 30, 2016 10:00 AM EDT Reads: 2,266
May. 30, 2016 09:15 AM EDT Reads: 2,793
May. 30, 2016 09:15 AM EDT Reads: 2,359
May. 30, 2016 09:00 AM EDT Reads: 1,417
May. 30, 2016 08:00 AM EDT Reads: 2,379
May. 30, 2016 07:15 AM EDT Reads: 1,393
May. 30, 2016 07:00 AM EDT Reads: 2,242
May. 30, 2016 06:00 AM EDT Reads: 2,011
May. 30, 2016 05:30 AM EDT Reads: 3,300
May. 30, 2016 04:45 AM EDT Reads: 3,321
May. 30, 2016 03:45 AM EDT Reads: 1,392
May. 30, 2016 03:15 AM EDT Reads: 1,540
May. 30, 2016 03:00 AM EDT Reads: 1,397
May. 30, 2016 03:00 AM EDT Reads: 2,089
May. 30, 2016 02:45 AM EDT Reads: 1,083